Yang Chen, Sun Li, Zhang Lingxin, Zhou Lixin, Niu Dongfeng, Cao Wenfeng, Li Zhongwu, Huang Xiaozheng, Kang Qiang, Jia Lin, Platik Marina, Liu Xiuli, Lai Jinping, Cao Dengfeng
Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, MO 63110, USA.
These two authors contributed equally to this project.
Gastroenterology Res. 2018 Jun;11(3):221-230. doi: 10.14740/gr1015w. Epub 2018 May 31.
Special AT-rich sequence-binding protein 2 (SATB2) is a novel marker for colorectal adenocarcinomas but little is known about its expression in appendiceal adenocarcinomas. We aim to investigate SATB2 in these tumors and colorectal adenocarcinomas with comparison to CDX2.
Immunohistochemical stains for SATB2 and CDX2 were performed in 49 appendiceal adenocarcinomas (23 conventional, 26 adenocarcinoma ex goblet cell carcinoids (AdexGCCs)) and 57 colorectal adenocarcinomas. Their expression was correlated with tumor differentiation and growth patterns.
SATB2 staining was positive in 26/26 (100%) appendiceal AdexGCCs and 15/23 (65%) appendiceal conventional adenocarcinomas (P = 0.001). Their mean percentage of SATB2-positive cells was 93% and 34%, respectively (P < 0.0001). CDX2 staining was seen in 26/26 (100%) AdexGCCs and 22/23 (96%) appendiceal conventional adenocarcinomas (P = 0.4694). SATB2 and CDX2 showed similar staining in AdexGCCs but CDX2 labeled more tumor cells than SATB2 in conventional adenocarcinomas (mean 84% vs. 34%, P < 0.0001). SATB2 and CDX2 staining was seen in 82% (47/57) and 96% (55/57) colorectal adenocarcinomas, respectively (P = 0.01). The mean percentage of cells positive for SATB2 and CDX2 was 48% and 91%, respectively (P < 0.00001). Decreased SATB2 immunoreactivity was associated with non-glandular differentiation particularly signet ring cells in colorectal (P = 0.001) and appendiceal conventional adenocarcinomas (P = 0.04) but not in appendiceal AdexGCCs.
SATB2 is a highly sensitive marker for appendiceal AdexGCCs with similar sensitivity as CDX2. In colorectal and appendiceal conventional adenocarcinomas, SATB2 is not as sensitive as CDX2 and its immunoreactivity is dependent on tumor differentiation.
富含AT序列结合蛋白2（SATB2）是结直肠腺癌的一种新型标志物，但对其在阑尾腺癌中的表达了解甚少。我们旨在研究这些肿瘤及结直肠腺癌中的SATB2，并与尾型同源盒转录因子2（CDX2）进行比较。
对49例阑尾腺癌（23例传统型、26例杯状细胞类癌腺癌（AdexGCCs））和57例结直肠腺癌进行SATB2和CDX2免疫组织化学染色。它们的表达与肿瘤分化和生长模式相关。
SATB2染色在26/26（100%）例阑尾AdexGCCs和15/23（65%）例阑尾传统腺癌中呈阳性（P = 0.001）。SATB2阳性细胞的平均百分比分别为93%和34%（P < 0.0001）。CDX2染色在26/26（100%）例AdexGCCs和22/23（96%）例阑尾传统腺癌中可见（P = 0.4694）。SATB2和CDX2在AdexGCCs中显示出相似的染色，但在传统腺癌中CDX2标记的肿瘤细胞比SATB2多（平均84%对34%，P < 0.0001）。SATB2和CDX2染色分别在82%（47/57）和96%（55/57）的结直肠腺癌中可见（P = 0.01）。SATB2和CDX2阳性细胞的平均百分比分别为48%和91%（P < 0.00001）。SATB2免疫反应性降低与结直肠（P = 0.001）和阑尾传统腺癌（P = 0.04）中的非腺性分化尤其是印戒细胞相关，但在阑尾AdexGCCs中无此关联。
SATB2是阑尾AdexGCCs的一种高度敏感标志物，其敏感性与CDX2相似。在结直肠和阑尾传统腺癌中，SATB2不如CDX2敏感，且其免疫反应性取决于肿瘤分化。
